The term "anabolic" means to use body energy to promote growth and regulate constructive metabolism. Androgen use has become a major public health concern due to the transition of use of androgens from strictly sports to a much a wider spectrum of the population. Androgens stimulate and precipitate the development of male sex characteristics. Anabolic-androgenic steroids (AAS) are steroidal androgens which include natural androgens such as male sex hormone testosterone or could be synthetic to mimic the action of the endogenous male hormone. Anabolic steroids and androgens are medically prescribed (orally or injectable) to treat hormonal imbalance for conditions such as hypogonadism, impotence in men, delayed puberty in adolescent boys, breast cancer in women, endometriosis, osteoporosis, and muscle loss in patients with cancer or HIV. However, some people misuse anabolic steroids for various reasons. For example, athletes abuse anabolic steroids to enhance performance and prolong endurance. Non-athletic people misuse anabolic steroids to increase body weight and lean muscle mass without increasing fat mass in the body. The potential side effects from anabolic steroid abuse are significant, and health care providers should be aware of patients at risk of anabolic-androgenic steroid misuse.
Anabolic-steroid misuse can occur at any age. Approximately 3 to 4 million Americans used anabolic-androgenic steroids to increase muscle mass whether for sports to increase their performance or cosmetic purposes such as enhancing their appearance. People who have misused steroids may possibly be suffering muscle dysmorphia which is a behavioral syndrome. The popular term used for the anabolic steroids is “steroids,” and other common names are "roids," "juice," "andro," "gear," and "stackers."
Due to the increasing prevalence of androgen misuse, the potential health hazards of anabolic steroids are increasing; however, the risk of androgen abuse is probably highly underestimated. Many surveys on drug abuse/misuse do not include steroids. A study in Germany showed that 48.1% of androgen steroid abusers who frequented fitness centers received their supply from healthcare providers. In a 2006 survey of 500 anabolic-androgenic steroids users, 78.4% were nonathletic and noncompetitive bodybuilders. A meta-analysis of 187 studies demonstrated that being athletic and/or male were significant predictors of anabolic steroids abuse. Moreover, the data revealed that the prevalence of males was 6.4%, compared to 1.6% in females. The method of choice for administration for the majority of AAS users (99.2%) was self-administrable injections. Of concern was that as high as 13% reported unsafe practices for injecting the steroids, such as sharing needles, reusing the same needles, and sharing vials.
Androgens help in the development of male secondary characteristics. Therefore, a female who uses anabolic-androgen steroids will note side effects such as hirsutism, acne, temporal male-pattern hair recession, deepening of the voice, and clitoromegaly. Some women will experience oligomenorrhea or even amenorrhea, as well as breast atrophy. The long term complication from exogenous androgens intake in men is hypogonadism. Exogenous androgens intake suppress the normal testicular function (sperm and testosterone production). Eventually, with prolonged use, testicular volume decreases which leads to a compromise of male fertility. In a retrospective study, 21% of 382 men with hypogonadism receiving testosterone treatment reported taking exogenous androgens. For men who have a history of taking androgens and then stopping them, the sperm count returns to normal after approximately four months to a year. Older men would take a longer time to recover than younger men after discontinuation. Androgen intake may lead to low sperm count, small testes, high hemoglobin and hematocrit values, low serum to non-detectable serum LH, and low sex hormone-binding globulin. These findings should raise the suspicion of exogenous androgen intake in men who are competing in sports.
The clinician might suspect exogenous intake of androgens in the following situations:
Exogenous administration of androgens should be suspected in a patient who is in a competitive sport or activity, demonstrating changes of behavior such as aggression, depression or irritability, or showing blood work changes such as deficient luteinizing hormone (LH) concentration, high hematocrit, and low sex hormone-binding globulin (SHBG).
Patients who misuse steroids are usually reluctant to stop taking them because of the potential side effects during withdrawal. Withdrawal symptoms include fatigue, sleep problems, loss of appetite, decreased libido, and steroid cravings. Among the most serious withdrawal symptoms is depression which could lead to suicidal ideation and attempts. Steroids do not precipitate the same type of high as many other drugs; however, patients who abuse steroids could are diagnosable with substance use disorder. Studies have shown that patients who misuse steroids could potentially use other drugs to help and reduce side effects such as depression, irritability, and lack of sleep.
The potential adverse cardiovascular effects from long-term anabolic steroid use are significant, and health care providers need to bring awareness among patients and implement protocols to help detect patients at risk.
Clinicians should target treating depression, body-image, and dysmorphia and associated detrimental behavioral patterns at groups who are at risk of anabolic-androgenic steroid abuse.
|||Higgins JP,Heshmat A,Higgins CL, Androgen abuse and increased cardiac risk. Southern medical journal. 2012 Dec; [PubMed PMID: 23211503]|
|||Penning R,Veldstra JL,Daamen AP,Olivier B,Verster JC, Drugs of abuse, driving and traffic safety. Current drug abuse reviews. 2010 Mar; [PubMed PMID: 20088818]|
|||Dawson RT, Drugs in sport - the role of the physician. The Journal of endocrinology. 2001 Jul [PubMed PMID: 11431137]|
|||Kaushik M,Sontineni SP,Hunter C, Cardiovascular disease and androgens: a review. International journal of cardiology. 2010 Jun 25; [PubMed PMID: 19923015]|
|||Alquraini H,Auchus RJ, Strategies that athletes use to avoid detection of androgenic-anabolic steroid doping and sanctions. Molecular and cellular endocrinology. 2018 Mar 15; [PubMed PMID: 28130115]|
|||Iyer R,Handelsman DJ, Androgens. Frontiers of hormone research. 2016 [PubMed PMID: 27347677]|
|||Ip EJ,Barnett MJ,Tenerowicz MJ,Perry PJ, The Anabolic 500 survey: characteristics of male users versus nonusers of anabolic-androgenic steroids for strength training. Pharmacotherapy. 2011 Aug; [PubMed PMID: 21923602]|
|||Parkinson AB,Evans NA, Anabolic androgenic steroids: a survey of 500 users. Medicine and science in sports and exercise. 2006 Apr; [PubMed PMID: 16679978]|
|||Sagoe D,Molde H,Andreassen CS,Torsheim T,Pallesen S, The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Annals of epidemiology. 2014 May; [PubMed PMID: 24582699]|
|||Givens ML,Deuster P, Androgens and Androgen Derivatives: Science, Myths, and Theories: Explored From a Special Operations Perspective. Journal of special operations medicine : a peer reviewed journal for SOF medical professionals. 2015 Fall [PubMed PMID: 26360363]|
|||Ip EJ,Lu DH,Barnett MJ,Tenerowicz MJ,Vo JC,Perry PJ, Psychological and physical impact of anabolic-androgenic steroid dependence. Pharmacotherapy. 2012 Oct; [PubMed PMID: 23033230]|
|||Ha ET,Weinrauch ML,Brensilver J, Non-ischemic Cardiomyopathy Secondary to Left Ventricular Hypertrophy due to Long-term Anabolic-androgenic Steroid Use in a Former Olympic Athlete. Cureus. 2018 Sep 17 [PubMed PMID: 30473946]|
|||Akbari Z,Esmailidehaj M,Avarand E,Shariati M,Pourkhalili K, Ischemic Preconditioning Efficacy Following Anabolic Steroid Usage: A Clear Difference Between Sedentary and Exercise-Trained Rat Hearts. Cardiovascular toxicology. 2018 Dec 7 [PubMed PMID: 30535662]|
|||Chistiakov DA,Myasoedova VA,Melnichenko AA,Grechko AV,Orekhov AN, Role of androgens in cardiovascular pathology. Vascular health and risk management. 2018 [PubMed PMID: 30410343]|
|||Vlad RA,Hancu G,Popescu GC,Lungu IA, Doping in Sports, a Never-Ending Story? Advanced pharmaceutical bulletin. 2018 Nov [PubMed PMID: 30607326]|
|||Ganson KT,Cadet TJ, Exploring Anabolic-Androgenic Steroid Use and Teen Dating Violence Among Adolescent Males. Substance use & misuse. 2019 [PubMed PMID: 30572768]|
|||Guzzoni V,Selistre-de-Araújo HS,Marqueti RC, Tendon Remodeling in Response to Resistance Training, Anabolic Androgenic Steroids and Aging. Cells. 2018 Dec 7 [PubMed PMID: 30544536]|
|||Rasmussen JJ,Selmer C,Østergren PB,Pedersen KB,Schou M,Gustafsson F,Faber J,Juul A,Kistorp C, Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study. PloS one. 2016 [PubMed PMID: 27532478]|
|||Collomp K,Buisson C,Gravisse N,Belgherbi S,Labsy Z,Do MC,Gagey O,Dufay S,Vibarel-Rebot N,Audran M, Effects of short-term DHEA intake on hormonal responses in young recreationally trained athletes: modulation by gender. Endocrine. 2018 Mar [PubMed PMID: 29322301]|
|||Fink J,Schoenfeld BJ,Nakazato K, The role of hormones in muscle hypertrophy. The Physician and sportsmedicine. 2018 Feb [PubMed PMID: 29172848]|
|||Bailey K,Yazdi T,Masharani U,Tyrrell B,Butch A,Schaufele F, Advantages and Limitations of Androgen Receptor-Based Methods for Detecting Anabolic Androgenic Steroid Abuse as Performance Enhancing Drugs. PloS one. 2016 [PubMed PMID: 26998755]|